The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The objective of this study is to investigate the safety of intralesional (IL) PV-10 for the treatment of recurrent breast carcinoma. This study will also include a preliminary assessment of response of injected lesions by histologic assessment upon lesion excision at 1-3 weeks following IL PV-10 administration. Post-excision wound healing will be assessed clinically at 1 week and 4 weeks following excision of PV-10 injected lesions.
Condition or disease
Drug: PV-10 (rose bengal disodium 10%)
This is a single center, open label, ascending dose study. Subjects with at least one recurrent, histologically confirmed measurable soft tissue breast carcinoma who are candidates for lumpectomy (removal of the lesion from the site of recurrence in the breast or at another site) or mastectomy will receive a single intralesional injection of PV-10 into a single target lesion to uniformly infiltrate the target lesion and up to a 0.5 cm margin at a dose of up to 1.0 mL/cc lesion volume. Systemic and locoregional adverse events will be monitored over the study interval. Subject accrual and PV-10 administration will be stopped if more than 1 subject has a treatment related Grade 3 non-hematological or Grade 4 hematological toxicity within a period of two weeks after PV-10 administration.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 85 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Biopsy confirmed recurrent soft tissue breast carcinoma
At least one measurable target lesion at least 0.5 cm and no more than 3 cm in longest diameter
Performance Status: Karnofsky 70-100% or ECOG 0-2
Life Expectancy: At least 6 months
White blood cell count (WBC) at least 3000/mm3
Absolute neutrophil count (ANC) at least 1.5 (1,500/mm3)
Hemoglobin at least 10 g/dL
Platelet count at least 100,000/mm3
Coagulopathy: International Normalized Ratio (INR) at least 1.5.
Renal Function: Creatinine = 0.05-0.11 mmol/L
Bilirubin = 3-21 umol/L
AST/ALT ≤ 3 times the upper limit of normal (ULN)
Cardiovascular Function: No major cardiovascular disease
Thyroid Function: T3 (serum triiodothyronine), T4 (serum thyroxine) and THS (serum thyrotropin) within normal limits
Immunological Function: Adequate immune system function in the opinion of the investigator
Radiation therapy to study lesions within 4 weeks
Chemotherapy or other systemic cancer therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin)
Local treatment (e.g., surgery, cryotherapy, radiofrequency ablation) to the treatment area within 4 weeks
Investigational agents within 4 weeks (or 5 half-lives)
Anti-tumor vaccine therapy within 12 weeks
Severe diabetes or extremity complications due to diabetes
Significant concurrent disease or illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the investigator, compromise subject safety or compliance or interfere with interpretation of study results
Thyroid autoregulatory dysfunction, including thyroid disease (subclinical or ongoing), goiter, partial thyroidectomy, prior radioiodine- or surgically-treated Graves' hyperthyroidism, or cystic fibrosis
Pregnancy or fertile female subjects who are not using effective contraception, or who are lactating
Known or suspected brain metastases or spinal cord compression.